Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR: Brepocitinib in Adults With Dermatomyositis
NCT05437263Phase 3Completed
- Sponsor
- Priovant Therapeutics
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of brepocitinib in dermatomyositis (DM), sponsored by Priovant Therapeutics. Started Oct 2022; status: completed.
02
Drugs
brepocitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05437263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437263.